Project Grant R41HL176245
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$312K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Nytricx, Inc. (GF9DV4ACBHH8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,082,412 to the University of Pittsburgh to optimize and prepare for the manufacturing and regulatory submission of an immunoregulatory tissue-engineered vascular graft (TEVG) device. The key objectives are to: Evaluate the TEVG constructs in vitro using clinically-relevant measures, 2) Validate the performance of scaled-up, human-sized...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
This Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a unique antimicrobial vascular catheter to prevent catheter-related bloodstream infections (CRBSI). The $272,702 award, effective September 1, 2023, with a completion date of February 29, 2024, will support research and development efforts to create an intravascular catheter with inherent long-lasting antiseptic properties. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,865.00 to the University of Pittsburgh to develop an optimized, minimally invasive strategy to treat ischemic cardiomyopathy (ICM). The key products and services to be delivered include: Evaluating the functional, geometric, and histopathologic effects of injecting three different thermoresponsive hydrogel formulations into an ICM...